Search the Community
Showing results for tags 'interleukins'.
-
Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis (SpA) changes in patients with psoriasis. Our study can imply that IL-17A is a valuable, useful and low–cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA psoriatic patients. PubMed, Int J rheumatologist Dis, 10/05/2020. (Also see Interleukins and Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- spa
- ps and psa
-
(and 1 more)
Tagged with:
-
The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis. In this review, we summarize the current knowledge of the pathomechanism by focusing on the IL-23/IL-17 pathway. PubMed, Int J Mol Sci, 2020 Sep 3;21(17):E6401. (Also see Psoriasis and Psoriatic Arthritis and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- spondyloarthritis.
- interleukins
-
(and 1 more)
Tagged with:
-
Interleukin-32 in Systemic Sclerosis (SS), a Potential New Biomarker for Pulmonary Arterial Hypertension (PAH) Our study suggested that sera determination of IL-32 may be a promising approach to evaluate the presence of PAH in SSc patients. PubMed, Arthritis Res Ther, 2020 Jun 1;22(1):127. (Also see Interleukins and Pulmonary Hypertension Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- pah
- scleroderma
-
(and 2 more)
Tagged with:
-
Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. IL-31/IL-31RA is confirmed as a candidate pro-fibrotic pathway, which may contribute to skin and lung fibrosis in a subset of scleroderma patients. PubMed, Rheumatology (Oxford), 05/04/2020. (Also see Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
Interleukin-34 as a marker for subclinical proliferative lupus nephritis (LN). Serum IL-34 may be used as a surrogate marker for early renal affection in silent LN, especially the proliferative type. Sage Journals, Lupus, 04/01/2020. (Also see Symptoms and Complications of Lupus and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- interleukins
- lupus complications
-
(and 1 more)
Tagged with:
-
Cantargia Selects CAN10 as Development Project in Systemic Sclerosis and Myocarditis. Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP) and the project will focus on unmet medical need in systemic sclerosis and myocarditis. PR Newswire, 12/05/2019. (Also see Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- myocarditis
- systemic sclerosis
-
(and 1 more)
Tagged with:
-
The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis (SSc). Here, we aim to give a brief overview of IL-1 family cytokines and discuss their pivotal roles in the pathogenesis of SSc. PubMed, Front Immunol, 2019 Sep 13;10:2025. (Also see Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- scleroderma
- cytokines
-
(and 1 more)
Tagged with:
-
IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. The regional up-regulation of IL-16 in the skin is not only associated with skin sclerosis, but also with systemic IL-16 activation. PubMed, Rheumatology (Oxford), 08/03/2019. (Also see Skin Fibrosis and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- skin fibrosis
- interleukins
-
(and 1 more)
Tagged with:
-
Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis (SSc). Increased synthesis of IL-17B, IL-17E and IL-17F appears to play a role in the pathogenesis of SSc, in contrast to IL-17A. PubMed, Arch Med Sci, 2019 May;15(3):706-712. (Also see Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
Interleukin-17 pathways in systemic sclerosis–associated fibrosis. There is multitude of evidence from across different tissues that interleukin-17 (IL-17) and its downstream pathways are strongly associated with the initiation and propagation of fibrosis. PubMed, Rheumatol Int, 05/09/2019. (Also see Interleukins and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- scleroderma
- skin fibrosis
-
(and 1 more)
Tagged with:
-
Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus (SLE) and lupus nephritis (LN). These results indicate that for active LN, sTNF-R1 could be a useful serum cytokine marker, with potential for vascular endothelial growth factor in the urine. PubMed, Lupus, 2019 May 2:961203319845487. (Also see Diagnosis of Lupus and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis (SSc). The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. PubMed, Ann rheumatologist Dis, 05/31/2018. (Also see Interleukins and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- interleukins
- clinical trials
-
(and 2 more)
Tagged with:
-
The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis? Recent analyses of the IL-1 family of cytokines have demonstrated that many of them play a role in skin inflammation and fibrosis and their corresponding antagonists (IL-1RA and IL-36RA) can abrogate this pathology. PubMed, Immunol Lett, 12/04/2017. (Also see Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- interleukins
- cytokines
-
(and 1 more)
Tagged with: